Regulation of G1 cell cycle progression: Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s)

Genes and Cancer

Volumn 1, Issue 11, 2010, Pages 1124-1131

  Foster, David A ^a   Yellen, Paige ^a   Xu, Limei ^a   Saqcena, Mahesh ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cancer; Cell cycle; Cyclins; Mtor; Quiescence; Rb; Restriction point; Start; Tgf

Indexed keywords

GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN;

CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH CHECKPOINT; CELL TRANSFORMATION; DRUG TARGETING; GENETIC TRANSFORMATION; HUMAN; MITOSIS; NEOPLASM; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; RESTRICTION POINT; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 79960048104     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910392989     Document Type: Review

References (83)

1. Sherr CJ. Cell cycle control and cancer. Harvey Lect. 2000-2001;96:73-92.
2. Weinberg RA. pRb and control of the cell cycle clock. In: The biology of cancer. New York: Garland Science; 2007. p. 255-307.
3. Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 2002;12:47-52.
4. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Curr Opin Cell Biol. 1995;7:835-42.
5. Donovan J, Slingerland J. Transforming growth factor-ß and breast cancer: cell cycle arrest by transforming growth factor-ß and its disruption in cancer. Breast Cancer Res. 2000;2:116-24.
6. Lodish H, Berk A, Kaiser CA. Regulating the eukaryotic cell cycle. In: Molecular cell biology. 6th ed. New York: WH Freeman; 2007. p. 853-98.
7. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974;71:1286-90.
8. Hartwell LH, Culotti J, Pringle JR, Reid BJ. Genetic control of the cell division cycle in yeast. Science. 1974;183:46-51.
9. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-8.
10. Hahn WC, Dessain SK, Brooks MW, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002;22:2111-23.
11. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39-85.
12. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103-12.
13. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14:152-60.
14. Petritsch C, Beug H, Balmain A, Oft M. TGF-ß inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 2000;14:3093-101.
15. Boehm JS, Hession MT, Bulmer SE, Hahn WC. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol. 2005;25:6464-74.
16. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem. 1999;274:22033-40.
17. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene. 1998;17:1457-62.
18. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497-510.
19. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-74.
20. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412:179-90.
21. Avruch J, Long X, Lin Y, et al. Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem Soc Trans. 2009;37:223-6.
22. Sun Y, Fang Y, Yoon MS, et al. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A. 2008;105:8286-91.
23. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29:1411-20.
24. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochem Biophys Acta. 2009;791:949-55.
25. Bai X, Ma D, Liu A, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science. 2007;318:977-80.
26. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
27. Akagi T. Oncogenic transformation of human cells: shortcomings of rodent model systems. Trends Mol Med. 2004;10:542-8.
28. Kendall SD, Adam SJ, Counter CM. Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle. 2006;5:1074-9.
29. Pardee AB. G1 events and regulation of cell proliferation. Science. 1989;246:603-8.
30. Coller HA. What's taking so long? S-phase entry from quiescence versus proliferation. Nat Rev Mol Cell Biol. 2007;8:667-70.
31. Ekholm SV, Zickert P, Reed SI, Zetterberg A. Accumulation of cyclin E is not a prerequisite for passage through the restriction point. Mol Cell Biol. 2001;21:3256-65.
32. Martinsson HS, Starborg M, Erlandsson F, Zetterberg A. Single cell analysis of G1 check points-the relationship between the restriction point and phosphorylation of pRb. Exp Cell Res. 2005;305:383-91.
33. Yen A, Pardee AB. Exponential 3T3 cells escape in mid-G1 from their high serum requirement. Exp Cell Res. 1978;116:103-13.
34. Yen A, Pardee AB. Arrested states produced by isoleucine deprivation and their relationship to the low serum produced arrested state in Swiss 3T3 cells. Exp Cell Res. 1978;114:389-95.
35. Jorgensen P, Rupes I, Sharom JR, Schneper L, Broach JR, Tyers M. A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size. Genes Dev. 2004;18:2491-505.
36. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-62.
37. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-71.
38. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004:24:200-16.
39. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/ eIF4E. Genes Dev. 2002;16:1472-87.
40. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle. 2002;1: 103-10.
41. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220-7.
42. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol. 2001;21:4773-84.
43. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98:859-69.
44. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005;24:2776-86.
45. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753-61.
46. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signalregulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J. 1997;326:61-8.
47. Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate. 1998;35:117-24.
48. Fan J, Bertino JR. K-Ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997;14:2595-607.
49. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017-21.
50. Herrera RE, Sah VP, Williams BO, Mäkelä TP, Weinberg RA, Jacks T. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol. 1996;16:2402-7.
51. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432:298-306.
52. Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell. 2006;9:75-6.
53. Chen CR, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor-ß growth arrest program. Proc Natl Acad Sci USA. 2001;98:992-9.
54. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-ß/ ALK5-mediated Smad3 activation. EMBO J. 2006;25:58-69.
55. Gadir N, Jackson D, Lee E, Foster DA. Defective TGF-ß signaling sensitizes human cancer cells to rapamycin. Oncogene. 2008;27:1055-62.
56. Gadir N, Lee E, Garcia A, Toschi A, Foster DA. Suppression of TGF-ß signaling by phospholipase D. Cell Cycle. 2007;6:2840-5.
57. Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature. 1985;318:472-5.
58. Lu Z, Hornia A, Jiang YW, et al. Tumor-promotion by depleting cells of protein kinase Cd. Mol Cell Biol. 1997;17:3418-28.
59. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol. 1998;18:839-45.
60. Johnston GC, Pringle JR, Hartwell LH. Coordination of growth with cell division in the yeast Saccharomyces cerevisiae. Exp Cell Res. 1977;105:79-98.
61. Koff A, Cross F, Fisher A, et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 1991;66:1217-28.
62. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell. 1991;66:1197-206.
63. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2009;296:E592-602.
64. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915-28.
65. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedins and plateletderived growth factor. Proc Natl Acad Sci USA. 1979;76:1279-83.
66. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006;25:6347-60.
67. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214-26.
68. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563-75.
69. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606-19.
70. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle. 2007;6:2902-5.
71. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003;1:789-800.
72. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005;7:533-45.
73. Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007;258:268-75.
74. Garcia A, Zheng Y, Zhao C, et al. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 2008;14:4267-74.
75. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol. 2001;3:165-72.
76. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596-602.
77. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell. 2003;114:431-43.
78. Parisi T, Beck AR, Rougier N, et al. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J. 2003;22:4794-803.
79. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007;8:149-60.
80. Foster DA, Gadir N. Can defective TGF-ß signaling be an Achilles heel in cancer? Chin J Cancer. 2008;27:882-4.
81. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008;452:553-63.
82. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006;5:2606-12.
83. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway. Oncogene. 1998;17:769-80.